Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:approvalYear |
2021-03-26
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurologic toxicities |
| gptkbp:form |
cell suspension
|
| gptkbp:genericName |
gptkb:idecabtagene_vicleucel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Abecma
|
| gptkbp:indication |
multiple myeloma
relapsed or refractory multiple myeloma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:bluebird_bio
gptkb:Bristol_Myers_Squibb |
| gptkbp:mechanismOfAction |
targets BCMA (B-cell maturation antigen)
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
infections neutropenia neurotoxicity thrombocytopenia cytokine release syndrome |
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:treatment |
autologous cell therapy
|
| gptkbp:website |
https://www.abecma.com/
|
| gptkbp:bfsParent |
gptkb:gene_therapy
|
| gptkbp:bfsLayer |
5
|